| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Ipratropium Bromide (Sch 1000; Sch1000; Atrovent, Apovent, Ipraxa, Rinatec) is a potent antagonist of M3 type muscarinic acetylcholine receptors that opens up the medium and large airways in the lungs. It is used for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis.
| ln Vitro |
Toxic effects of ipratropium bromide (1 nM, 10 nM, 100 nM; 15 minutes) are caused by disruption of the potential of the mitochondrial membrane [1]. In ischemia/reperfusion tests on isolated perfused hearts, ipratropium bromide (1 nM-1 μM; 4 h) increases infarct size in a dose-response manner (EC50=22.7 nM) [1]. Adult rat cardiomyocytes grown in hypoxia for 4 hours are inhibited in growth by ipratropium bromide (0.001 nM-0.1 mM; 2 h) [1].
|
|---|---|
| ln Vivo |
The effects of vagus nerve stimulation-induced bronchoconstriction are amplified by ipratropium bromide (1.0 μg/kg; IV; single dosage) [2]. By lowering neutrophil parenchymal inflammatory infiltrate inflammation, ipratropium bromide (0.04 mg/20 mL and 0.20 mg/20 mL; 30 min, rate=30 mL/30 min) shields the lung against cadmium-induced acute neutrophil infiltration[4].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Adult Rat Cardiac Myocyte Tested Concentrations: 0.001 nM-0.1 mM Incubation Duration: 2 h in dark; prior to 4 h hypoxia Experimental Results: Resulted cell viability in a dose-dependent manner, with the inhibition rate of 52.7% at 0.1 mM dose. |
| Animal Protocol |
Animal/Disease Models: Guinea-pigs of the Dunkin Hartley strain[2].
Doses: 0.1-1 μg/kg Route of Administration: intravenous (iv) injection; single dose Experimental Results: Resulted little blocking effect on post-junctional muscarinic receptors at 0.3 μg/kg, and inhibited ACh-induced bronchoconstriction at 0.5 μg/kg. Animal/Disease Models: Male SD (Sprague-Dawley) rats (300-350 g)[4] Doses: 0.04 mg/20 mL and 0.20 mg/20 mL Route of Administration: Inhalation; atomization rate of 30 mL/ 30 min; 30 min Experimental Results: Had no significant effects on any parameters recorded in healthy rats but exerted a protective effect against the inflammatory reaction elicited by cadmium. |
| References |
[1]. Fryer AD, et al. Maclagan, Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea-pig. Eur J Pharmacol, 1987. 139(2): p. 187-91.
[2]. Harvey, et al. Maddock, Ipratropium Bromide-Mediated Myocardial Injury in In Vitro Models of Myocardial Ischaemia/Reperfusion. Toxicol Sci, 2014. [3]. Maria Prat, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl amides as potent and long acting muscarinic antagonists. Bioorg Med Chem Lett. 2015 Apr 15;25(8):1736-1741. [4]. Wenhui Zhang, et al. Anti-inflammatory effects of formoterol and ipratropium bromide against acute cadmium-induced pulmonary inflammation in rats. Eur J Pharmacol. 2010 Feb 25;628(1-3):171-8. |
| Molecular Formula |
C20H30BRNO3
|
|---|---|
| Molecular Weight |
412.37
|
| CAS # |
22254-24-6
|
| Related CAS # |
Ipratropium-d3 bromide;Ipratropium-d7 bromide;Ipratropium bromide hydrate;66985-17-9
|
| SMILES |
O=C(OC1C[C@]([N+]2(C)C(C)C)([H])CC[C@]2([H])C1)C(C3=CC=CC=C3)CO.[Br-]
|
| InChi Key |
LHLMOSXCXGLMMN-CLTUNHJMSA-M
|
| InChi Code |
InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18?,19?,21?;
|
| Chemical Name |
[(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;bromide
|
| Synonyms |
Sch-1000; ipratropium bromide, Sch 1000; Sch1000; trade names: Atrovent, Apovent, Ipraxa, Rinatec
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (121.25 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4250 mL | 12.1250 mL | 24.2501 mL | |
| 5 mM | 0.4850 mL | 2.4250 mL | 4.8500 mL | |
| 10 mM | 0.2425 mL | 1.2125 mL | 2.4250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA